Technology
Health
Biotechnology

Neon Therapeutics

$3.57
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.56 (-13.56%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell NTGN and other stocks, options, ETFs, and crypto commission-free!

About NTGN

Neon Therapeutics, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. Read More The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA.

Employees
102
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
101.14M
Price-Earnings Ratio
Dividend Yield
Average Volume
255.15K
High Today
$4.15
Low Today
$3.49
Open Price
$4.11
Volume
345.21K
52 Week High
$13.00
52 Week Low
$3.49

Collections

Technology
Health
Biotechnology
2018 IPO
US
North America

NTGN Earnings

-$0.84
-$0.78
-$0.73
-$0.67
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.76 per share
Actual
Expected Aug 5, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.